Clinical studies and meta-analyses show that GLP-1R agonists reduce the risk of major adverse cardiovascular events (MACE) by 10–14%, including cardiovascular mortality, nonfatal myocardial infarction, stroke and all-cause mortality, in patients with T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.